Chemical formula: C₁₉H₁₈F₃N₃O₂ Molecular mass: 377.367 g/mol PubChem compound: 11610526
Lasmiditan is a high affinity, centrally-penetrant, 5-hydroxytriptamine 1F (5-HT1F) receptor agonist. The precise mechanism of action is unknown, however, the therapeutic effects of lasmiditan in the treatment of migraine presumably involve agonistic effects at the 5-HT1F receptor, a decrease of neuropeptide release and an inhibition of pain pathways, including the trigeminal nerve.
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| RAYVOW Film-coated tablet | European Medicines Agency (EU) | MPI, EU: SmPC | |
| REYVOW Tablet | FDA, National Drug Code (US) | MPI, US: SPL/PLR |
Lasmiditan is an active ingredient of these brands:
United States (US)Austria (AT)Croatia (HR)Estonia (EE)France (FR)Ireland (IE)Italy (IT)Japan (JP)Lithuania (LT)Spain (ES)Turkey (TR)
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
